Exhibit 107
Calculation of Filing Fee Tables
S-3
(Form Type)
Eledon Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or
Carry Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Offering Price |
Fee Rate |
Amount of Registration Fee |
Carry Forward Form Type |
Carry Forward File Number |
Carry Forward Initial Effective Date |
Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |||||||||||||
| Newly Registered Securities | ||||||||||||||||||||||||
| Fees to Be Paid |
Equity | Common Stock, par value $0.001 per share |
Rule 457(o) | (1) | (2) | (1)(2) | ||||||||||||||||||
| Equity | Preferred Stock, par value $0.001 per share |
Rule 457(o) | (1) | (2) | (1)(2) | |||||||||||||||||||
| Debt | Debt Securities | Rule 457(o) | (1) | (2) | (1)(2) | |||||||||||||||||||
| Other | Warrants | Rule 457(o) | (1) | (2) | (1)(2) | |||||||||||||||||||
| Other | Units | Rule 457(o) | (1) | (2) | (1)(2) | |||||||||||||||||||
| Unallocated (Universal) Shelf | — | Rule 457(o) | (1) | (2) | $250,000,000 | 0.00014760 | $36,900 | |||||||||||||||||
| Fees Previously Paid |
— | — | — | — | — | — | — | |||||||||||||||||
| Carry Forward Securities | ||||||||||||||||||||||||
| Carry Forward Securities | — | — | — | — | — | — | — | — | — | |||||||||||||||
| Total Offering Amounts | $250,000,000 | $36,900 | ||||||||||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||||||||||
| Total Fee Offsets | $27,275(3) | |||||||||||||||||||||||
| Net Fee Due | $9,625 | |||||||||||||||||||||||
Table 2: Fee Offset Claims and Sources
| Registrant or Filer Name |
Form or Filing Type |
File Number |
Initial Filing |
Filing Date |
Fee Offset |
Security Type with Fee Offset |
Security Title Associated with Fee Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Amount with Fee Offset |
Fee Paid with Fee Offset Source | ||||||||||||
| Rule 457(p) | ||||||||||||||||||||||
| Fee Offset Claims |
Eledon Pharmaceuticals, Inc. | S-3 | 333-254890 | 3/31/2021 | $27,275(3) | Unallocated (Universal) Shelf |
(3) | (3) | $250,000,000 | |||||||||||||
| Fee Offset Sources | Eledon Pharmaceuticals, Inc. | S-3 | 333-254890 | 3/31/2021 | $27,275 | |||||||||||||||||
| (1) | There is being registered hereunder an unspecified number of shares of (a) common stock, (b) preferred stock, (c) debt securities, (d) warrants to purchase common stock, preferred stock or debt securities of the Registrant, and (e) units, consisting of some or all of these securities in any combination, as may be sold from time to time by the Registrant. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. There is also being registered hereunder an unspecified number of shares of common stock, preferred stock and debt securities as shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance. In no event will the aggregate offering price of all types of securities issued by the Registrant pursuant to this registration statement exceed $250,000,000. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction. |
| (2) | The proposed maximum offering price per share and proposed maximum aggregate offering price for each type of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act. |
| (3) | On March 31, 2021, the Registrant filed a Registration Statement on Form S-3 (File No. 333-254890) (the “Prior Registration Statement”), which registered an aggregate amount of $250,000,000 of common stock, preferred stock, debt securities, warrants and units to be offered by the Registrant from time to time. In connection with the filing of the Prior Registration Statement, the Registrant made a contemporaneous fee payment in the amount of $27,275. The Prior Registration Statement has expired and all offerings thereunder have been completed or terminated. Accordingly, securities having an aggregate offering price of $250,000,000 were not sold under the Prior Registration Statement. As a result, the Registrant has $27,275 in unused filing fees associated with the Prior Registration Statement that remain available to offset filing fees payable pursuant to this registration statement in accordance with Rule 457(p). |